Incannex Healthcare Limited (IXHL)
USD 0.5
(-3.86%)
USD 0.5
(-3.86%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 210 Thousand USD | 0.0% |
| 2023 | 407.8 Thousand AUD | 0.0% |
| 2022 | - AUD | 0.0% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| 2018 | - AUD | -100.0% |
| 2017 | 397.45 Thousand AUD | 7.53% |
| 2016 | 369.62 Thousand AUD | 0.0% |
| 2015 | - AUD | -100.0% |
| 2014 | 925.56 Thousand AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | -100.0% |
| 2011 | 832.61 Thousand AUD | -16.74% |
| 2010 | 1 Million AUD | -84.11% |
| 2009 | 6.29 Million AUD | 9700.05% |
| 2008 | 64.2 Thousand AUD | 19.66% |
| 2007 | 53.65 Thousand AUD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 301 Thousand USD | 0.0% |
| 2024 Q3 | 248 Thousand USD | 0.0% |
| 2024 Q4 | 210 Thousand USD | 0.0% |
| 2023 Q4 | 407.8 Thousand AUD | 0.0% |
| 2023 FY | 407.8 Thousand AUD | 0.0% |
| 2023 Q2 | 123.48 Thousand AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 FY | - AUD | 0.0% |
| 2022 Q4 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2021 FY | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 FY | - AUD | 0.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| 2019 Q4 | - AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2018 FY | - AUD | -100.0% |
| 2018 Q2 | 200 Thousand AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2017 FY | 397.45 Thousand AUD | 7.53% |
| 2017 Q4 | 397.45 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 Q4 | 369.62 Thousand AUD | 300.0% |
| 2016 FY | 369.62 Thousand AUD | 0.0% |
| 2016 Q3 | 92.4 Thousand AUD | -74.15% |
| 2016 Q2 | 357.43 Thousand AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2015 Q1 | 231.39 Thousand AUD | -75.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q2 | - AUD | -100.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2015 FY | - AUD | -100.0% |
| 2014 FY | 925.56 Thousand AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q2 | 895.68 Thousand AUD | 0.0% |
| 2014 Q3 | 231.39 Thousand AUD | -74.17% |
| 2014 Q4 | 925.56 Thousand AUD | 300.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 Q3 | - AUD | -100.0% |
| 2013 Q2 | 470.28 Thousand AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2012 Q2 | - AUD | -100.0% |
| 2012 FY | - AUD | -100.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q1 | 208.15 Thousand AUD | -75.0% |
| 2011 Q1 | 250 Thousand AUD | -75.0% |
| 2011 Q4 | 832.61 Thousand AUD | 300.0% |
| 2011 FY | 832.61 Thousand AUD | -16.74% |
| 2011 Q3 | 208.15 Thousand AUD | -79.18% |
| 2011 Q2 | 1 Million AUD | 300.0% |
| 2010 Q4 | 1 Million AUD | 300.0% |
| 2010 Q2 | 6.31 Million AUD | 303.37% |
| 2010 Q1 | 1.56 Million AUD | -75.1% |
| 2010 FY | 1 Million AUD | -84.11% |
| 2010 Q3 | 250 Thousand AUD | -96.04% |
| 2009 Q4 | 6.29 Million AUD | 301.69% |
| 2009 Q3 | 1.56 Million AUD | 567.91% |
| 2009 Q2 | 234.51 Thousand AUD | 0.0% |
| 2009 FY | 6.29 Million AUD | 9700.05% |
| 2009 Q1 | - AUD | -100.0% |
| 2008 Q2 | 85.47 Thousand AUD | 0.0% |
| 2008 Q4 | 64.2 Thousand AUD | 0.0% |
| 2008 FY | 64.2 Thousand AUD | 19.66% |
| 2008 Q1 | - AUD | -100.0% |
| 2008 Q3 | - AUD | -100.0% |
| 2007 FY | 53.65 Thousand AUD | 0.0% |
| 2007 Q4 | 53.65 Thousand AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | 93.082% |
| Safety Shot Inc | 304.9 Thousand USD | 31.127% |
| Bright Green Corporation | 201.78 Thousand USD | -4.072% |
| Embecta Corp. | 1.62 Billion USD | 99.987% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.932% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.769% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.957% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.917% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.958% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 98.424% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.959% |
| PainReform Ltd. | 30 Thousand USD | -600.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 61.041% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 61.041% |
| SCYNEXIS, Inc. | 12.15 Million USD | 98.273% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -79.29% |
| Journey Medical Corporation | 14.62 Million USD | 98.564% |
| Alpha Teknova, Inc. | 13.25 Million USD | 98.415% |
| Procaps Group, S.A. | 28.41 Million USD | 99.261% |
| Theratechnologies Inc. | 51.26 Million USD | 99.59% |
| Harrow Health, Inc. | 183.17 Million USD | 99.885% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -141.379% |
| Biofrontera Inc. | 804 Thousand USD | 73.881% |
| DURECT Corporation | 2.7 Million USD | 92.228% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 99.367% |
| Cronos Group Inc. | 1.55 Million USD | 86.53% |
| OptiNose, Inc. | 611 Thousand USD | 65.63% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.958% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.386% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 53.846% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 99.654% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 98.357% |
| Radius Health, Inc. | 339.66 Million USD | 99.938% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 97.953% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.954% |
| Procaps Group S.A. | 28.41 Million USD | 99.261% |
| Alvotech | 1.02 Billion USD | 99.98% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 96.785% |
| Viatris Inc. | 16.18 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 8.29 Million USD | 97.468% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 98.069% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | 37.498% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.927% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 99.826% |
| Shineco, Inc. | 10.01 Million USD | 97.904% |
| PetIQ, Inc. | 437.82 Million USD | 99.952% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.919% |
| Alimera Sciences, Inc. | 64.48 Million USD | 99.674% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 99.455% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -55.453% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 96.938% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 70.833% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -833.998% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 99.359% |
| Hempacco Co., Inc. | 5.93 Million USD | 96.459% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.98% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.626% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.966% |
| Currenc Group, Inc. | 2.5 Million USD | 91.623% |
| Kamada Ltd. | 7.43 Million USD | 97.177% |
| Indivior PLC | 235.66 Million USD | 99.911% |
| Evoke Pharma, Inc. | 5 Million USD | 95.8% |
| Flora Growth Corp. | 942 Thousand USD | 77.707% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -833.998% |
| Evolus, Inc. | 120.35 Million USD | 99.826% |
| HUTCHMED (China) Limited | 48.18 Million USD | 99.564% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.964% |
| Akanda Corp. | 2.49 Million USD | 91.59% |